Sudden olfactory loss as an early marker of COVID-19: a nationwide Italian survey.

PURPOSE: The presence of many asymptomatic COVID-19 cases may increase the risks of disease dissemination, mainly for physicians. There are numerous reports on the frequent findings of sudden anosmia or hyposmia, before or at the same time of the typical COVID-19 symptoms onset. The aim of this study was to verify the association of olfactory impairment and COVID-19, providing a basis for subsequent research in the field of COVID-19 clinical heterogeneity.
METHODS: We developed a 15-item online questionnaire on "Sudden Olfactory Loss (SOL) and COVID-19" that was administered during March 2020 to Italian general practitioners registered to a social media group.
RESULTS: One hundred and eighty responses were received. SOL was identified as a significant sign of infection in COVID-19 patients, mainly aged between 30 and 40 years, even in the absence of other symptoms. SOL was present as an initial symptom in 46.7% of subjects, and in 16.7%, it was the only symptom. Among the COVID-19 confirmed cases, SOL occurred as the only symptom in 19.2% of patients.
CONCLUSION: SOL could represent a possible early symptom in otherwise asymptomatic COVID-19 subjects. Subjects affected by SOL should be considered as potential COVID-19 cases. LEVEL OF EVIDENCE: 4.

Introduction

In late December 2019, the appearance of clusters of patients with pneumonia of unknown cause was reported for the first time in Wuhan, China [1]. In the first reports of this condition, the Chinese scientists identified the responsible pathogen in a novel strain of coronavirus (CoV) found in bronchoalveolar-lavage samples of the patients affected by severe pneumonia. Next-generation sequencing analysis indicated that the unknown genome showed more than 85% identity with those of a bat SARS-like CoV [2]. In January 2020, the Chinese authorities shared the full sequence of the novel coronavirus genome and made the data available to researchers worldwide. This novel coronavirus was later designated as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the disease named as Coronavirus disease 2019 (COVID-19) in February 2020 by the World Health Organization (WHO) [3, 4]. Thus far, SARS-CoV-2 had spread worldwide and the WHO, on March 11, declared COVID-19 a pandemic with the sustained risk of further global spread [5-7].

Currently, the human-to-human transmission is believed to occur through respiratory aerosol, droplets from coughing and sneezing, and indirect transmission. Close contacts with affected subjects can thus lead the spread of COVID-19 to growth exponentially in a short time, especially in the presence of milder symptomatic or asymptomatic people. The use of precautionary hygiene measures and the early identification of suspected subjects, including those with atypical presentations, are crucial to prevent cross-infections. The clinical features of COVID-19 largely resemble those observed for SARS-CoV and MERS-CoV infections: the most recurrent traits are fever, dry cough, dyspnoea, and bilateral ground-glass opacities on chest computed tomography scans, while fewer patients present with intestinal signs and symptoms [8, 9].

In such a scenario, there is a growing body of reports of paucisymptomatic or clinically atypical cases of COVID-19, who represent potential “silent carriers” of infection. This is even more relevant for healthcare professionals, at elevated risk of exposure, who may be at the same time victims of and unknowing responsible for new cases of disease [10, 11].

In this perspective study, we aimed at investigating the atypical or paucisymptomatic presentation of COVID-19 by the presence of sudden olfactory loss (SOL) [12-18], making hypotheses about the pathophysiological mechanism of SOL in COVID-19. At the same time, we investigated whether this symptom can represent an early marker of the disease and whether it can be used to identify otherwise asymptomatic subjects.

Materials and methods

We developed a pilot survey named “Sudden Olfactory Loss and COVID-19”. To gather data from a geographically dispersed sample in a short time, we used an Internet-based 15-item questionnaire, posted on a social media closed group of Italian general practitioners. Reports were collected during March 2020.

The aim of this survey was to anonymously collect details from patients complaining of SOL with regards to the assumed correlation with COVID-19 infection, similarly to studies performed in other countries [19].

The survey was administered to general practitioners who evaluated subjects complaining olfactory impairment in the study period. These patients were selected on the basis of sudden onset of the olfactory disturbance during the COVID-19 outbreak in Italy. The main exclusion criterion was a positive anamnesis for previous olfactory alterations.

Questionnaire was designed and administered using Google Forms; responses were collected in an online Excel spreadsheet; questionnaire took < 10 min to complete. Access to the online spreadsheet was limited to the principal investigator. Questions were mostly close ended. In this pilot phase, we added a final open-ended question aiming to identify further key responses. Informed consent to the use of anonymised data was provided in the questionnaire.

The questionnaire was composed of five sections: (a) respondents’ workplace, age, and sex of the patient; (b) general information about the risk of exposure to COVID-19, asking to specify if the patient is a healthcare professional; (c) clinical information: onset of symptoms, grade of olfactory loss (OL) with three subjective levels (mild, moderate, and severe/complete), presence or absence of: ageusia, hypogeusia and/or dysgeusia gathered together under the name of “taste symptoms”; nasal discharge and/or congestion, other accompanying symptoms (e.g., fever, fatigue, dry cough, dyspnoea, and myalgia), comorbidities and complications; d) execution and results of nasopharyngeal (NP)/oropharyngeal (OP) swab; e) short description about the clinical case.

Data were analysed using Statistical Packages for Social Sciences (SPSS), version 26 (SPSS Inc., Chicago, IL, USA).

Results

From March 11th to March 31st 2020, we collected 180 unique responses (180 patients) from 100 Italian general practitioners. Three Italian practitioners reported some cases also from European hospitals, where they currently work. Geographic distribution is shown in Fig. 1. At the time of the study, Lombardy, Emilia-Romagna, and Piedmont were the most affected regions by COVID-19 outbreak.

Fig. 1

Geographic distribution of sudden olfactory loss cases across Italy, by region, from March 11th to March 31st, 2020

SOL occurred in 104 (57.8%) females and 76 (42.2%) males, with a female-to-male ratio of 1.37. The mean age was 39.6 years (SD ± 10.9; median 37.0) with a range of 21–82 years. Half of the population was between 30 and 40 years (47.2%, n = 85), while the less represented group was over 59 years old (5.5%) (Table 1). Among the recruited patients, 115 (63.9%) had contact with other suspected or confirmed COVID-19 cases and 84 (46.7%) were healthcare professionals.

Table 1

Baseline features of patients affected by sudden olfactory loss

	Years
Age, mean (DS), median (range)	39.6 (±10.9), 37.0 (21–82)
	No. (%)
Sex
Female	104 (57.8)
Male	76 (42.2)
F:M ratio	1.37
Health care professionals	84 (46.7)
Comorbidities
Ca rdiovascular disease	9 (5.0)
Chronic tireopathy	6 (3.3)
Immunological disorders	5 (2.8)
Malignancy	4 (2.2)
Respiratory disease	4 (2.2)
Gastrointestinal disease	3 (1.7)
Genetic disease	3 (1.7)
Obesity	1 (0.5)
Genitourinary disorders	1 (0.5)
Chronic rhinosinusitis	1(0.5)
Sign and symptoms
Fever,  °C	108 (60.0)
> 37 < 37.5	50 (27.8)
>37.5<38	31 (17.2)
> 38 <38.5	14 (8.7)
> 38.5	13 (7.2)
Fatigue	88 (48.9)
Dry cough	85 (47.2)
Myalgia	73 (40.5)
Nasal discharge/obstruction	63 (35.0)
Headache	28 (15.5)
Dyspnea	15 (8.3)
Pharyngalgia	14(7.8)
Diarrhoea	12 (6.7)
Conjunctivities	10(5.5)
Nausea/appetite loss	10 (5.5)
Chest pain	2 (1.1)
Burning tongue sensation	2 (1.1)
Phantosmia	2 (1.1)
Dizziness	2 (1.1)
Complications
Interstitial pneumonia	7 (3.9)
Total sample	180 (100.0)

Olfactory dysfunction

Olfactory dysfunction was categorized into three subjective levels of severity: 65.6% of patients (n = 118) complained about severe/total loss (severe hyposmia/anosmia), whereas the others were moderately (27.2%, n = 49) or slightly (7.2%, n = 13) affected (hyposmia), respectively. The majority of cases (92.2%, n = 166) presented olfactory dysfunction in combination with taste disturbances (Fig. 2).

Fig. 2

The impact of olfactory impairment and association with taste symptoms

Mixed responses were collected on the duration of olfactory impairment, mostly reporting the persistence of the OL at the time of the completion of questionnaire, or a slight improvement within 7–20 days. Only 11 subjects experienced a complete remission of olfactory symptoms that lasted between 2 and 10 days.

Accompanying symptoms

The accompanying symptoms are summarized in Table 1. The mean time of SOL onset before or after the first typical COVID-19 symptom (fever, dry cough, and dyspnoea) was 2.4 days (SD ± 2.7); anosmia/hyposmia occurred as the first symptom in 46.7% of cases, as sole symptom in 16.7% of cases or in association with other clinical manifestations in 31.2% of patients.

Analysing the relationship with the fever, in 45.5% of cases, SOL occurred within 7 days of fever onset; in 40%, it was present without fever; in 14.4%, there was a contemporary appearance. In our cases, fever never followed anosmia. Most of the patients showed a low-grade fever (37–37.5 °C) (Table 1).

SOL occurred without discharge and/or nasal congestion in 117 (65.0%) subjects.

Notably, no accompanying symptom were reported in 30 (16.7%) cases, only one in 24 (13.3%) cases, 2 or 3 in 82 (45.5%) cases, and more than 4 symptoms in 44 (24.4%) cases.

Thirty-seven patients (20.5%) had coexisting medical conditions. Interstitial pneumonia affected 7 patients (Table 1).

Confirmed COVID-19

NP/OP swabs for SARS-CoV-2 testing were made in 29 (16.1%) subjects (Fig. 3). The other patients did not meet screening criteria for swab test. Twenty-six patients (89.6%) tested positive, four of which without history of COVID-19 contacts (15.4%). The symptoms timeline is described in Fig. 4. Twelve subjects were apyretic (46.1%). Notably, among the COVID-19 confirmed cases, SOL occurred in the initial phase, as the only symptom, in 5 patients (19.2%).

Fig. 3

Results of screening testing for SARS-CoV-2

Fig. 4

Symptoms timeline in COVID-19 confirmed patients: case series of 26 subjects evaluated from March 11th to March 31st, 2020

Interstitial pneumonia due to SARS-CoV-2 was described in five confirmed cases. A 57-year-old female showed moderated SOL and taste complaints with common cold as the only symptoms during the week before clinical presentation of interstitial pneumonia.

Discussion

The nasal mucosa has a high relative permeability, thin endothelial membrane, and reasonable surface area for absorption of small molecules, as well as macromolecules such as proteins and peptides, nucleotides, viruses, and even stem cells. Intranasal delivery is emerging as a reliable method to reach Central Nervous System (CNS) by-passing the blood–brain barrier for a wide range of agents, from small molecules like drugs, to large elements such as viral vectors, growth factors, and stem cells [20, 21]. The inhaled microorganisms and particles pass first through the nasal cavity, which is largely covered by the respiratory epithelium and mainly contains olfactory sensory neurons, which have cilia exposed to the environment, allowing contact with particles. Each olfactory receptor neuron projects a dendrite into the nasal cavity on the apical side, and on the basal side extends its axon through the cribriform plate into the olfactory bulb (OB) of the brain. The axons of the olfactory neurons are a gate to the OB and provide a direct pathway to the CNS. Some viruses, like Influenza and Herpes simplex, exploit this olfactory pathway to access the OB, from which they can spread to other brain regions, as described in various animal models of infection [22].

Pathophysiological explanations of olfactory impairment in COVID-19

Neurotropic and neuro-invasive capabilities for several coronavirus (CoV) strains have been described in their hosts, including humans. However, the capacity of CoV to infect the CNS in humans is still unclear, and mainly based on the detection of viral RNA [8]. A route for neuroinvasion is the transport through olfactory neurons [23]. The olfactory nerve is in communication with the nasal epithelium and the olfactory bulb, providing a unique gateway to the CNS [8]. The previous studies have shown the ability of SARS-CoV to invade brain mainly via the olfactory nerve [20, 23, 24], and thereafter rapidly spread to some specific brain areas, including thalamus and brainstem, causing neuronal death in transgenic mice [20]. This localization could suggest an involvement of solitary tract and ambiguous nuclei, both playing a key role in the regulation of respiratory mechanisms [24, 25]. The progression of the COVID-19 virus to the brain via the cribriform plate, close to the olfactory bulb, can be an additional pathway that could enable the virus to reach and affect the brain. Huang et al. reported that some patients infected with SARS‐CoV‐2 showed neurologic signs such as headache (about 8%), nausea, and vomiting (1%) [9]. Additionally, findings such as an altered sense of smell or hyposmia in uncomplicated early stage COVID-19 patients should be investigated thoroughly for CNS involvement [22]. The neuroinvasive propensity has been demonstrated as a common feature of CoV, and, due to the similarity between SARS‐CoV and SARS‐CoV-2, it is plausible that SARS‐CoV‐2 possesses a similar potential [25, 26].

A further hypothesis on nasal involvement considers tear drainage: the virus may enter the tears through droplets, which pass through the nasolacrimal ducts and then into the respiratory tract [23]. The propagation of the virus particle through the olfactory route follows the mechanisms already seen in several viruses. Furthermore, the identification of 13 different sialic acids in mouse brain, including the olfactory bulbs [27] as well as other tissues, together with the ability of CoV OC43 to interact with 5-N-acetyl-9-0-acetyl neuraminic acid via hemagglutinin-esterase surface glycoprotein [28, 29] and the spike glycoprotein [30], may suggest sialic acids as a potential mechanism of entry of SARS-CoV-2 in the CNS.

Association between olfactory impairment and COVID-19

The available pathophysiological basis supports the association between SOL and COVID-19. Our results also demonstrated the exact geographical coincidence between the distribution of SOL cases and COVID-19 cases. In fact, the territories affected the most by the infection at the time of the investigation coincide with the areas where SOL has been reported the most. In our study, the age distribution of SOL, regardless of its subjective severity, indicated that the symptom is more present in the population aged between 30 and 40 years, as opposed to the major epidemiologic studies that reports the highest estimates in the elderly [31]. Moreover, olfactory impairment is generally unrecognized, because it appears gradually, and self-reports of smell disturbance underestimate the levels of dysfunction detected by quantitative tests [32]. In this perspective, it is striking that in our study, the onset of olfactory dysfunction was not gradual but sudden, with patients being fully aware of this symptom.

In our sample, most patients with complete OL also reported taste alteration. Based on our observations, the taste disorder appears to be likely secondary to the olfactory disorder rather than support the hypothesis of a distinct transmission pathway of the virus to the CNS via the lingual nerve [24].

The anamnestic data are particularly important for the demonstration of the correlation of SOL with COVID-19. In our study, 63.9% of patients had documented exposure to COVID-19 affected subjects. Unfortunately, the confirmation of positivity is only available for a small part of the study population (14.4%), as the criteria for the screening procedure with a swab did not match the characteristics of most of our patients. Nevertheless, it is possible to deduce this correlation from the frequent association with other typical symptoms of COVID-19, and from comparison with the percentage of patients tested positive (89.6%), which makes us believe that the majority of the sample could be affected.

It is interesting to note that fever, the symptom most frequently used for COVID-19 screening, is present in some studies in less than 50% of subjects, at least in the initial stages of the disease, although fever developed in 88.7% of cases during hospitalization [33]. This undermines the validity of fever as a screening marker for COVID-19, since it may fail to identify subjects in the early stages of the disease. This hypothesis is confirmed in our sample, in which fever, albeit still the most frequent symptom, was present only in 60% of SOL subjects. In particular, SOL was the only symptom in five (19.2%) of the cases confirmed by positive swab test.

Moreover, the analysis of the association between fever and OL revealed that in 40% of cases, OL was present in the absence of fever, and in 14.4% of cases, there was a contemporary appearance of the two symptoms, while fever never followed anosmia. Therefore, using fever as a screening tool may result ineffective in the initial stages of the disease that represent those with the highest viral load and with the greater risk to spread infection. In fact, patients with COVID-19 appear to have the highest viral load near presentation, which could account for the fast-spreading nature of this epidemic [34]. In the confirmed positive cases of our sample, fever was absent in 46.1% of subjects, and not considering SOL would have led to losing nearly 20% of the subjects. These subjects were under the age of 50, therefore those with more intense social/work activity and therefore at greater risk of spreading the virus.

This finding emphasises the importance of stringent infection control. Introducing OL together with fever could also greatly increase the sensitivity of a clinical screening tool for COVID-19.

In our case history, the appearance of SOL frequently preceded the typical symptoms of COVID-19 or occurred within 2.4 days (± 2.7) from the appearance of the other symptoms. The pathophysiological hypotheses of the neuroinvasiveness of this virus would support this finding [24]. Based on a recent epidemiological survey on COVID‐19, the median time from the first symptom to dyspnoea was 5 days, to hospital admission was 7 days, and to the intensive care was 8 days [35]. The temporal data reinforce the importance of considering SOL as an early marker of infection, until proven otherwise.

Finally, among the recruited patients, 84 (46.7%) were healthcare professionals: our data confirm that their risk of exposure is extremely high, especially in the absence of adequate individual protection devices and in cases without full-blown symptoms.

Conclusion

Our data suggest that subjects with SOL without obstructive nasal conditions should be considered as potential COVID-19 cases. SOL could represent a possible early marker to identify asymptomatic subjects and to reduce the spread of the infection. Viral shedding from nasal secretions, sneezing, coughing, and sputum can be continuous up to 6 weeks, which builds concerns that asymptomatic individuals could also transmit the infection for such long time. Therefore, it should be recommended to avoid nasal treatments (i.e., nasal washing, spray, and invasive manoeuvres) that could amplify the virus dissemination.

Our preliminary results provide a basis for subsequent research in the field of clinical heterogeneity of COVID-19 and identify a possible clinical marker to increase the sensitivity of screening procedures and limit the spread of the infection through appropriate prevention programs.